Filing Details
- Accession Number:
- 0001209191-19-043024
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-07-24 16:17:33
- Reporting Period:
- 2019-07-22
- Accepted Time:
- 2019-07-24 16:17:33
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1759425 | Mirum Pharmaceuticals Inc. | MIRM | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1341382 | N James Topper | 70 Willow Road, Ste. 200 Menlo Park CA 94025 | No | No | Yes | No | |
| 1720320 | Frazier Life Sciences Ix, L.p. | 70 Willow Road, Ste. 200 Menlo Park CA 94025 | No | No | Yes | No | |
| 1782789 | Fhmls Ix, L.p. | 70 Willow Road, Ste. 200 Menlo Park CA 94025 | No | No | Yes | No | |
| 1782791 | Fhmls Ix, L.l.c. | 70 Willow Road, Ste. 200 Menlo Park CA 94025 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-07-22 | 3,116,912 | $0.00 | 3,116,912 | No | 4 | C | Direct | |
| Common Stock | Acquisiton | 2019-07-22 | 450,000 | $15.00 | 3,566,912 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2019-07-22 | 24,935,300 | $0.00 | 3,116,912 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Direct |
Footnotes
- In connection with the Issuer's initial public offering, each share of the Issuer's Series A Preferred Stock automatically converted into 0.125 shares of the Issuer's Common Stock. The shares have no expiration date.
- The shares are held directly by Frazier Life Sciences IX, L.P. FHMLS IX, L.P. is the general partner of Frazier Life Sciences IX, L.P. FHMLS IX,L.L.C. is the general partner of FHMLS IX, L.P. James N. Topper and Patrick Heron are the managing members of FHMLS IX, L.L.C.and share voting and dispositive power over the shares held by Frazier Life Sciences IX, L.P. Mr. Topper, FHMLS IX, L.P. and FHMLS IX, L.L.C. disclaim beneficialownership of the shares held by Frazier Life Sciences IX, L.P., except to the extent of his or its pecuniary interest therein, if any.
- The shares were purchased in the Issuer's initial public offering.
Billionaire Hedge Funds
